This week in Drug Discovery (2 – 6 February)
News round-up for 2 – 6 February by Bruno Quinney, Content Team at DDW.
This week in DDW, innovative therapies could pave the way to more effective cancer treatments. Elsewhere, how can brain function be improved in Alzheimer’s patients?
The top stories:
Immunotherapy before surgery could better treat melanoma
New research, published in Nature Cancer, shows that 71% of desmoplastic melanoma patients who received the immunotherapy drug pembrolizumab before surgery had no detectable cancer remaining at the time of surgery.
FDA clears first cancer gene therapy for trials
The US Food and Drug Administration (FDA) has cleared Siren Biotechnology’s first Investigational New Drug (IND) application for its AAV immuno-gene therapy for cancer, enabling the initiation of its first-in-human clinical trial.
Therapy could improve brain function in Alzheimer’s patients
An investigational therapy could improve cognition, function and brain atrophy measures in Alzheimer’s patients, data shows.
Sugar-targeting antibody could kill drug-resistant bacteria
Researchers have designed antibodies that recognise the sugar found only on bacterial cells, which could underpin a new generation of immunotherapies for multidrug resistant hospital-acquired infections.
UK government commits £1.5bn to life sciences
Speaking at the BioIndustry Association (BIA)’s Gala Dinner, Liz Kendall, the Secretary of State for Science, Innovation and Technology, confirmed the funding for life sciences as part of the government’s pledge to scrap short-term funding cycles for key R&D institutions.
